Signal A $200 million public-private partnership was announced in March 2026 to fund further trials

Summary

The report observes that in March 2026 the US National Cancer Institute announced a public-private partnership worth $200 million. The money is intended to fund further trials of personalized cancer vaccines. The report reads the announcement as a sign that the field has moved beyond proof of concept. It follows clinical results such as 90% survival among immune responders in a pancreatic cancer study and a 49% cut in recurrence or death risk in melanoma. The outlook adds that scaling up will require sequencing, vaccine design and manufacturing to function as one pipeline. It also calls for financing mechanisms that make these therapies accessible beyond well-resourced health systems.